CHMP recommends authorisation for Revlimid (lenalidomide) in mantle cell lymphoma- Celgene
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Revlimid (lenalidomide), from Celgene, indicated the drug for the treatment of adult patients with relapsed or refractory mantle cell lymphoma.
Comment: Patents for the drug are various and many expire in 2019 but Celgene has a polymorph patent that it claims could extend patent life to 2017. That may be questionable but two 'method of use' patents are stronger and expire in 2023.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.